Jinan Jiage biological technology co., LTD(expird)
Free supplier
- Free
supplier - 8th
years
Free supplier
Business Type:Trading Company
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Trading Company
CAS NO.10238-21-8
Enterprise standard(1-10)GramEnterprise standard(11-100)Gram
1,High quality with competitive price
1)Standard: Enterprise Standard
2)All Purity≥99%
3)We are manufacturer and can provide high quality products with factory price.
2,Fast and safe delivery
1)Parcel can be sent out in 24 hours after payment. Tracking number available
2)Secure and discreet shipment. Various transportation methods for your choice.
3)Customs pass rate ≥99%
4)We have our own agent/remailer/distributor who can help us ship our products very fast and safe, and we have stock in there for transferring.
3,We have clients throughout the world
1)Professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet their desire.
2)Market feedback and goods feedback will be appreciated, meeting customers's requirement is our responsibility.
3) High quality,competitive price,fast delivery ,first-class service gain the trust and praise from the customers.
High purity Pharmaceutical Glibenclamide for antidiabetic
|
Synonyms |
GLYBENCLAMIDE;GLYBENZCYCLAMIDE;GLYBURIDE;GIBENCLAMIDE |
|
CAS NO |
10238-21-8 |
|
MF |
C23H28ClN3O5S |
|
MW |
494 |
|
Purity |
99% |
|
Appearance |
White Crystalline Powder |
|
Certification |
ISO 9001， USP， BP |
|
Standard |
Enterprise standard |
|
Usage |
Glyburide is a second generation sulfonylurea with hypoglycemic activity. Glyburide is an antidiabetic. |
|
Packing |
Discreet packing ways as your requirement, 100% go through |
|
Storage |
Store in cool and dry area and keep away from direct sunlight |
Description:
Glibenclamide belongs to the second generation oral sulfonylurea drugs with the mechanism of action being
similar as tolbutamide and the hypoglycemic effect being strongest among sulfonylurea drugs. Its intensity of
action is about 200 to 250 times of that of Tolbutamide. It can selectively act on the pancreatic β-cells, promote
insulin secretion; can enhance the hypoglycemic effect of exogenous insulin and strengthen the post-receptor
effect of insulin. It has fast oral absorption with high protein binding rate.
Effects:
Glibenclamide is currently one of the most commonly used drugs for the treatment of type 2 diabetes. Because
this product has fast and strong effect, so the effect after the application remarkable, being able to have good
control of blood sugar; being applicable for patients of high blood sugar who get bad efficacy when treated with
other sulfonyl Urea hypoglycemic agents.
Two commonly sulfonylurea oral hypoglycemic agents are glibenclamide and glimepiride, the comparison of
hypoglycemic effect of them two are as follow:
(1) The effect on glucose transport and metabolism: Glibenclamide and glimepiride can stimulate the key
enzymes in the glucose metabolism and improve the glucose transporter (GLUT4) translocation /
dephosphorylation to promote the glucose uptake of the surrounding tissue, specifically exhibited in glycogen
synthesis and increased fat formation. Glycogen synthase and 3-phosphoglycerol fatty acyltransferase are the
key enzymes in glycogen and fat synthesis, and glimepiride is more active than glibenclamide in activating
these key enzymes, such as for activating glycogen synthase activity, glimepiride is 2.5 times that of
glibenclamide; for the capability to activate lipase, glimepiride is 1.9 times that of glibenclamide. Glimepiride
increased the expression of GLUT4 on the cell membrane by inducing dephosphorylation of GLUT4.
(2) Effect on glycosylated-phosphatidylinositol-specific phospholipase (GPI-PLC): GPI is located in the outer
layer of the cell membrane and participates in insulin signal transduction, which can interfere with glucose
metabolism of muscle and adipocytes. GPI-PLC can shed the GPI, thereby improving the cell phosphorylation
status. Insulin and sulfonylureas can activate GPI-PLC, helping muscle, adipose tissue for the uptake and
transport of glucose.
However, in the presence of insulin resistance, insulin itself is very difficult to activate GPI-PLC, but glimepiride
can still activate the enzyme. In vitro and in vivo studies have shown that, glimepiride has the strongest
pancreatic effect in sulfonylurea drugs, which can increase glucose synthesis by 2.5 times and fat synthesis by
4 times.The ratio of glimepiride to glibenclamide was 2: 1. Therefore, glimepiride has a lower secondary failure
incidence than other sulfonylurea drugs.